**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED** ## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT)** ## **YEAR ENDED 31 AUGUST 2021** The trustees, who are also directors of the charity for the purposes of the Companies Act 2006, present their report and unaudited financial statements of the charity for the year ending 31 August 2021. ## **Trustees** The trustees, who are also the directors for the purposes of company law, and who served during the year and up to the date of signature of the unaudited financial statements were: Prof J Newell-Price Prof J Ramage Prof T H Shah Prof C Thirlwell – appointed 2 December 2019 None of the directors has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of winding up. The Society has two main categories of membership as follows: Clinician and Consultant Members; Trainee, Nurse, Scientist and Allied Health Professional Members. The latter are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or organisations interested in promoting the objects. ## **Governing document** The UK and Ireland Neuroendocrine Tumour Society Limited (UKI NETS) is constituted by its Memorandum & Articles of Association, adopted by the membership on 1 December 2014, and is a registered charity. UKI NETS became a company limited by guarantee on 13 August 2008 and was subsequently registered as a charity on 16 July 2012. ## **Organisational structure** The Society has two main categories of membership as follows: Clinician and Consultant Members; Trainee, Nurse, Scientist and Allied Health Professional Members. The latter are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or organisations interested in promoting the objects. The Society is governed by four Executive Officers, who are the directors and trustees (Chair, Past Chair, Treasurer and Secretary), supported by a wider Executive Committee, which includes chairs of the sub committees. ## **Risk management** The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. 1 **UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED** ## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT)** ## **YEAR ENDED 31 AUGUST 2021** ## **Objectives and activities** The charity’s objects are to promote for the public benefit research, education and clinical practice in neuroendocrine tumours by the organisation of conferences, training courses and publications, by raising public awareness, liaison with national and international legislators, and by any other appropriate means. The Society aims to improve the diagnosis and therapy of patients with neuroendocrine tumours within a national multidisciplinary and scientific context. In furtherance of its objects, the Society shall have the following powers: 1. To arrange and provide for the holding of meetings, lectures and seminars. 2. To procure to be written and print, publish, issue and circulate gratuitously or otherwise such papers, periodicals, pamphlets or other documents. 3. To raise funds and to invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any permanent trading activities in raising funds for its primary charitable objectives. 4. To co-operate, associate or affiliate with any other charitable institutions. 5. To do all such other lawful things as are necessary for the attainment of the above objectives. The summary of main activities in relation to the charity objectives are as follows: - Annual Scientific Meeting - Provision of travel grants - Provision of meeting awards - Allocation of research grants - Provision of educational activities - Guideline development - Public engagement ## **Achievements and performance** ## **UKI NETS 18[th] Annual Conference: Online 2020** The 18th Annual Conference of the Society was held Online on Monday 30 November 2020. This was the first time that the conference had been held virtually, due to the COVID-19 pandemic. The Society welcomed 208 people to the event, only 21 fewer than the previous years’ event which was held in London in 2019. Sessions ran from early afternoon until early evening, focusing on NET Diagnostic Approaches over the last 20 years from Surgical, Gastroenterology, Endocrinology, Medical Oncology approach and the Patient Perspective. ‘Challenging the Experts’ sessions reviewed three selected trainee case presentations, focusing on everyday NET challenges and inviting questions and discussion. Oral abstract presentations held on day 2 **UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED** 4 included topics such as Liver metastases of neuroendocrine neoplasms, Omic Gene Clusters and the challenges presented by COVID-19 to the NCUK care experience. The conference ended with a Prize Giving session. ## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT)** ## **YEAR ENDED 31 AUGUST 2021** ## **Provision of travel grants** As the conference was held online in 2020, no travel grants were awarded. ## **Provision of meeting awards** Prizes were awarded to the best scoring clinical and scientific posters and oral communication at the 18[th] Annual Conference. ## **Provision of Research grants** UKI NETS and the NET Patient Foundation awarded one research grant of £25k to provide pump-priming funds to support research a project aimed at improving outcomes for patients with Neuroendocrine Tumours. ## **Public Engagement** UKI NETS members speak regularly at regional events aimed to help NET patients across the UK in collaboration with the NET Patient Foundation and other organisations. ## **Educational activities** UKINETS organised a NETs for Newcomers Training Day (formerly NET Basics Day) that was postponed until May 2021 and held online, due to the COVID-19 pandemic. The aims of this training day were to give participants (including doctors of all specialties) in the management of Neuroendocrine Tumours and: 1. To feel confident to plan outpatient care and initial investigations for a patient with a NET 2. To be able to present the patient to the NET MDT including awareness of terminology 3. To independently manage side effects of carcinoid syndrome and commonly used treatments for NET tumours UKINETS continues to expand its Library of Bitesize Guidance which is available on the UKINETS website. These are accessible clinical documents relating to specific areas of NET management. Sessions included a Q&A with a panel of International experts and encouraged lots of interaction. ## **Dietitians’ Working Group** 3 **UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED** The chair of the dietitians’ working group remained as a co-optee on the Executive Committee. ## **Sponsor Support** There was financial support to the Society in the form of sponsorship from companies throughout the pharmaceutical industry. The majority of the funding was provided as sponsorship for the National Conference and NETs Basics Training Day. Sponsorship packages were developed by the Treasurer to give companies options for different levels and areas of support moving forwards. ## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT)** ## **YEAR ENDED 31 AUGUST 2021** ## **Website** The charity’s website provides an important tool to inform members and the general public about the activities of the Society. http://www.ukinets.org. ## **Communications** UKI NETS communicates with its members by means of a newsletter containing highlights from previous conferences, information on clinical trials and other Society news. In addition, the charity highlights on its website news stories from the media relating to the field of neuroendocrine tumours. The charity also has its own Twitter account @UKINETS. ## **PROMNET app** Along with the NET Patient Foundation, UKINETS continued to be involved in a project to develop a mobile application to empower patients with regards to managing their neuroendocrine tumour. The app gained IRAS approval in 2020 and will act as a tool for patients to track their symptoms, collect data and communicate with the clinical team. The development of the app was funded by Imaging Equipment Ltd. ## **Clinical Trials** The NET Clinical Studies Group which monitors and compiles summaries of clinical trials presents updates and reports at the UKINETS Annual Conference. The Research SubCommittee of UKINETS also aims to keep the UKINETs website and NET Patient Foundation up to date with trials that are currently recruiting. ## **COVID-19** UKINETS released guidance and statements regarding the evolving COVID-19 pandemic and its impact on NET patients and their HCPs. ## **Link with the European Neuroendocrine Tumour Society (ENETS)** UKI NETS continues to provide free membership to its members to its European partner Society, ENETS. Through membership of ENETS, UKI NETS members have access to the 4 **UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED** journal _Neuroendocrinology_ and a reduced rate for the ENETS annual conference _._ This inclusive membership is optional for trainees, nurses, scientists and allied health professionals. ## **Financial review** ## **Principal funding sources** Income to the Society is mainly generated through industry support, the annual conference and membership subscriptions. Personal donations/legacies are received on an ad hoc basis. ## **Reserves policy** The reserve policy takes into consideration the major risks that could face the Society. It is the policy of the Society to maintain unrestricted funds, which are the free reserves of the charity. The reserves are held at a level that ensures the financial viability of the Society. That level is deemed to be one that equates to a minimum of one year’s expenditure. The balance sheet indicates that there are £124,035 unrestricted funds as at 31 August 2021. This provides sufficient funds to cover management, administration and support costs. ## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT** ## **YEAR ENDED 31 AUGUST 2021** ## **Plans for future periods** The UKI NETS 19th Annual Conference is scheduled to be held virtually in December 2021 due to the coronavirus pandemic. The first day will celebrate the history of UKI NETS and Advances in NET Diagnostic Approach. Abstracts have been submitted as usual and prizes will be awarded to the highest scoring presentations during the conference. Other plans for the coming year include: - Holding a further NETs for Newcomers training event virtually in February 2021 due to its postponement in 2020 – held in May 2021. - Further developing the library of bite size clinical guidance for the website and reviewing older guidelines - Developing a Carcinoid Heart Disease Conference postponed from 2020 - Delivery of broader training for nurses, AHPs, GPs, junior doctors and other nonspecialists - Development of a liver transplantation delivery programme and associated service development and research opportunities, in collaboration with LAG, NHFBT and SIGTO. - Development of additional online content for UKI NETS members - UKI NETs coordination of European NET studies in the UK - NET dietetics survey and guidance - Annual conference plans to be confirmed in accordance with COVID-19 - Providing feedback on external clinical guidelines - Continuing to secure funding from corporate donors - Continuing to develop communications with members 5 ## **UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED** Working with other societies and foundations to fund and promote NETS knowledge and research The Trustees Report was approved by the Board of Trustees and signed on its behalf by: Prof T H Shah Trustee Dated: 6 Charlty Rogl$trallon Numb•r. 1148145 Company R•glstratlon Numb•r. 06672185 (England and Wal•$l UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 AUGUST 2021 UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED CONTENTS Page Legal 8ThJ aL*nML8tral￿P Trust￿. ReF¢vI 3to7 Indopendwl 0x￿1n￿8 r•Fryt StsieMenlofftha￿￿l Bolance sheel 10 Noi•s to th8 fin￿￿[ 8lat•m 11to17 UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED LEGAL AND ADMINSTRATIVE INFORMATION Tru8ts•s Prof J NewelkPrKe Prol J Ramage Prol T H Shah Prol C ThiThwell Rogl¥tered Offl¢• 138 DK3belh Bim)In9ham B5 6DR eh4rlty numb•r. 1148145 Comp•ny nurnb•r. ￿672185 Iwbt4rnd In E[¥￿ W8188) Ind•p•ndent Ex*mln•r Paul Bowaler BVSC kn￿￿r¢y Firsl Fb Liwry Pkc 35 Livèry Stye Birrningham 83 2PB UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY UMITED TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2021 The INstees, ore akn dnth¥ olts thontytrtho ofthe COM￿n￿5 X￿, present th* ler￿ and ffinarwl slalèM￿ts oflm thJity Ihe year eTh1mg 31 August 2021. Trustvs The tnjstees. who are akn the dwgdor5 purposes ofwnpany law. ar￿ wts) seNe*J duriThJ tt year and up to the dale ol s¥JnalU￿ G4 Ihg ynaudited fin*K¥l statements were.. ProlJ NewelkPri¢• ProfJ Ramag ProlT H Shah Prof C ThSth¥811 None ofthe dlrectors has any bgnrfwl kn18rost in Iho Company. AJ oflhe tsuslees ar• ol the 0￿panY and guaranlee lo conlributè £1 in the event of wndlr4J up. Th& Swety has tsvo mah ¢ateg0rns o1ThMbornh￿ as fdm.. Clinklan ar*J c￿sU￿nt IAembers,' Trainee. Nurse. S¢*niist and Heallh Profess￿n31 Membets. Tho ￿ller are 9Nen the option of memt4rship %Mlh orwlhout inclusN8 ENETS rnembershrp. Klember6hip ol tha ehkn is open to any madiral professk>nals e¢ organi$8b¢ns intOrnSt•d in k¥mliNJ th• obj*. Gov•rnlng docurn•nt The UK and Ir81and Neuroondoukn• ruft￿r s￿￿ty IUKI NEfsi1s by rts Marnorandum & ArtScl88 ofAssoua¢w. •J¢Wed by th6 n￿mbOrShip on 1 D8c8rnbeT 2014, and Ls a gist8r8d Charity. UKI NETS a ttfflpany limit￿ byguwani•e on 13 Augusi 2[￿ and was subs8quenUy reg￿tered as a ehw on 16 2012. OrganIsa￿onal strurtur• Th8 Society ha5 Iwo main • 0fm8mbe￿￿￿ aslckn¥s.' cffflh*n and Consuft8nt Members., Train88. Nurse. S¢wnlist and AAk8d He81th PmlessK)nd Membets. The18tteraro given the oP￿0n of membership or wilhwl i￿U$l¥e ENETS membership. Ilemborship 01th8 charity Is open lo any rnedical profeS￿n￿lS ￿ orgaThBatiws inlere5ted in prorTh)img the obJ"ects. The govemod bylw EXeryrt￿ Offror¥, who are d¥eclrYs and tntstees (Cha￿, Past Chair, Treasurer aThJ Socrelaryl, Sup￿*￿Ied by 8 ￿er Executiv8 Crynmittoo. ￿thd8s thairs of thè sub commmeoj. Rlsk management Th8 tsustees h8¥e a duty to *Jen*fy and review the rtsks lo whth the tharity i% exp05*J 8nd lo ertsufe UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIEff LIMITED TRUSTEES REPORT IINCLUDING DIRECTORS REPORn YEAR ENDED 31 AUGUST 2021 ObJectl¥es and actlvltlgs The chartvs are lo for tho puL*c b8nefft re5earth, aThJ din￿￿ practic* in neurnondo¢rine lumtyJr5 by ts ￿9￿15a￿l 0fcon1efer￿. traty)iThJ ctyJrses P￿4￿31￿￿$, by rnislny pU￿1C 8warws. Ikitson vrith natK¥MI aryj u)tematwal bgthlorn. and by any othor 8ppropriat• m&ans. The &Kiety aims lo Mnpro¥e tho diagr*xis aTrJ tt￿rnpy ol PaI￿nL$ ¥Ath In frJrfhor8nc• Of￿ obJ8Lts. thB Sco>9ty Sh￿ have Ihe Idbxll¥J pty*on'. 2. To procwg to bè ￿lI1£n aThJ pML put4Bh. orolhètwsa pap8r¥. perfodkaK pwn￿815 or01h8rth￿M8nts. 3. To raise funds ano to Invite arvj reLYrve conlrthliNs Irom any ￿rgon or petson5 whatsoovor by way 018ubxripknB Bnd olhen¥kn Ihat Ihg S￿ety 8haV not und&rtake any permanent tradlng a¢lfvODèg In r*151ng funds for ils primary tharltsble oblectlv¢s. S. To do all Wul lhlry ts arn rn¢*ssary fw tha awaknmwt Lrfthe at*M otloctfves. Th9 aummary el actMIM kn rBlalb)n to the dwNy as foUThYs: Annual sdenti￿ Megury of travel grants ol meet'ThJ awards Ikcaiion ol re￿arCh granls Provtsth of educalv)Tral actMOg8 Guwjelino do¥&lopn￿nI •)gagement Achlovements and performance UKI NETS 18" Annual Conf•rnnce.' OnlSne 20211 The 18th knnual Conlwencè Of￿ was o￿lne on m￿daY 30 November 2020. This w8S the first time Ihal Ihe conlererKe had bten hebj virtuaty. due lo COVID-19 par¥J8mic. The Swety ¥￿I¢￿e￿ 208 people to Ihe event. 21 Ihan ihe prtrvKX￿ years, ovont whith was hehl in London in 2019. S￿l0n5 ran frcrfn eady afternr￿ earty eveniry. loDJwg on NET DiagnostK Aptffoach8s over Ihe last 20 years from Surgical. Gastroenlerow. ErKkKrinolcgy. Medical Oncobgy approach aThJ Ihe Patient Perspecbve. 'ChaI￿n91n9 the Experts. 5e5sKJThs ieviewed Ihree sele¢ied trainee cas$ pfysentation5. fLKU5ing cfi trveryday NET thallerrfjes aThJ Mvitry quest￿)￿$ 8nd discuss￿￿. Oral abstracl presentat￿nS hdd on day 4 induded lgxs such as LNer metaslases of neuroendocn [￿plasM$. orn￿ Gene Clustefs a￿fj Ihe challerys prewted try COV1[￿19 lo the NCUK care èxperience. The conlerenr* ended vtith a Pnze GNiThJ sesstrjn. UK AND IRELAND NEUROENDOCRJNE TUMOUR SOCIEtY LIMITED TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2021 Provlslon of tra￿1 gr4nts As the ¢xnfererK¢ was h8id onlww wi 2020. rn)travd 9¢￿ts ￿¥￿ed. Provlslon of ma￿1n9 awards Prizes wefe awaryted bfr￿ aNJ sdentts F￿t￿5 aThJ ml 0)n￿uniCat￿)n at the 18tt Annual confe￿n¢*. Provislon of R￿arCh grnnts UKI NETS and th8 NET Paliellt FOUr￿￿)n orn fesearth grnnt ol £25k to pump. rning funds to suppcwt rgsèarch a al)￿j at imk¥fft pati*)ts Neuroendocrine fur>v)urs. Publlc Engagemènt VXI NETS members speak regul8rfy at regknial events aimd to NET pthnts rn Iha UK collaborati¢)n wlth lh8 NET Pa¢￿Trt FIYJnd*b￿ and other0rywl￿ftrJn$. Educatlonal acllvlts UKINETS ¢xganl$gd a NEf$ Tran￿￿j D8y Ilonrnrty NET èasks Dayl thatwas posiponed until May 2021 aTrJ hold onli￿, dv• lo the COVID-19 pandam*. The aims of thi5 irnining day wer? to give parbcipants lfftduding dcthrs of all ¥￿iè￿e$l ￿ tha managomgnt of Nour08ndocrfne Tur￿u￿ and.. 1. To lèal c4yffhlènt lo plan ￿ earn initial wNeslhJ8l*M$lora pthnt wilh a NET 2. To be ablè lo prea•nl thg palknt to the NEf MDT kK4wthrwJ 84Yarerw oltomilnc4ogy 3. To inde￿d￿ty manap sljg effKts of(•rtw)oid syrthm 8ThJ c¥)rNrthty tre8lmonts lor NET UKINETS cMllnues lo exp￿ its Ltrgry ol Brt6size GutyJanc¢ which is availabla OTh tho UKINETS website. These are %cessibk* dinkal dcojments relating to spocrfK area5 01 NET managernenl. Sessbns I￿Uded 3 OU with a parnl ol Intwnolh%wl 8rthw8ged of interad*￿. Dletltlans. Worklng Group Tha dwir ollh8 d*DiHns' gr(w r•marnd as a &>opt•& on the ExeoJiNe Cornmittoa. Sponsor Support Tharè was financ431 SUPF#JI to Ihg S(thty in lh8 lorm ol spMsu51¥) from Compan￿ throughout the pharnaceutul industry. Th8 maionty of the funding wa5 pr￿￿ed as sponsorship lor the Not￿rbal Conference and NET5 Basics Tra￿￿9 Day. packag85 ￿￿9 doyeloped by the Tr8a5ur8r lo gwe compani8s Opt￿ f¢x drflwwrt and 8r•as olsuFwI movir¥J fcThMds. UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIEfi UMrrED TRUSTEES REPORT IINCLUOING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2021 Webslt• Thg tharity's Thpytanittd m•nknern aThl the at*wl thè 8th￿es of the Sc¢wty. hll Uk￿e[S 0 Communl¢*lon8 UKI NETS corNnur￿#t¢s ￿￿th menknr3 by wra ola wMslettwthita•i¥w l*JhlvJhts from prewous tonference5, inlLwmalI￿ on dirivl Vots and other Swety news. In additr¢). the c highlKJhts on its w8b5rté sknriès th the med￿? to the fjehj of neuro8r*Jouine lunv)ur5. Tha aho has its tr*n Twittqrxc￿l QUKINETS. PROMNET app Abng wilh the NET Pabont F•J￿ali0n. UKINETS lo t¢ invcknd th a wojact to dwelop a mobile applKati¢)n to empow patients ￿ regards to m8naghig their ntLvoendwn8 tymour. Tho app 98ined IRAS approval in 2020 and as a pab.ents to thw sympIc￿$. colect data and wnmunkats *llh th• thicd tsam. Th• olthe app w8s lunded by Imaging Equipment Ltd. Cllnl¢al Trlals Thè NET Clinical Studie8 Gfoupvthkh rMnit(#s aTha cwrlès diftkal trlak k¥•60Thts updat85 and r8pxts 81 the UKINETS ATrnu￿ Conferene•. Th8 R85è8r¢h &JbComrnittee of UKINETS olso aims lo koep Ihe UKIN￿l and NEf Pati8nt up to datfrwlh trial$ thai are f4Jrrenlty rocruits'NJ. COWD-19 UKINEIS retsaS￿ guk1ance and slatem8nls t•J¥thJ COWO-19 pandemk ¥nd its impact on NET pat￿ts and thetr HCPS. Llnk wSth th• Europan N•uro•ndtxrfn• Tumour Socl•ty IENETS} UKI NETS continues lo provth free Mfrmbws￿ ts its m8mt4rn to ts Eurc9￿ parther Soryety. ENETS. Through membw5hip ol ENETS. UKI NETS fflemt*ts have x¢ess lo Iho wmal N•ufoend(tnnthtyand a ￿thj¢ed rato lor th8 ENETS annual ￿nIeTr￿e. Thi5 sndusiv memb6rship ¢$ opbrml l(* Iraine6s. wr58s, scientsts and albed heallh p¥ofessknnaLq. Financial review Principal funding sourc•s Incom8 to Ihe SrKiety is mainty gen8rdl8d lhr1x￿h industy SLW)rrt thg amual Conferen￿ aTrJ membwship sjbscripknns. Per50no1 dona1K)r￿e9￿￿ are r8ceNed ￿ aTr ad l¥x basis. UK AND IRELAND NEUROENOOCRINE TUMOUR SOCIETY LIMITEO TRUSTEES REPORT IINCLUDING DIRECTORS IIEPORT YEAR ENDED J1 AUGUST 2021 Re￿IVeS pollcy 11 o Ihe S¢oety ￿ WA•i ur4Estr￿ hmos. are lh• I￿ i*M￿Cl (41tr* th• The reseThts afÈ held ai a ￿Ve1 Ihal eThswes Ihe &￿ty That Jt¥el t5 defjm•d lo be on• thal equaiès 10 a of0￿ ye¥'s expendlure The baUwc• sheei ￿&C￿leS Ihll Iher• are £124 035 unrestrved fufids as ai 31 2021 5uffo¢N ioto¥•r managemeni. odmmistraixjn aThJ ￿￿P>T cosls Plans for fulure perlods The UKI NETS 19th AnfiU￿ r4 Schedu￿ robe hekl tmDJatyin O•centsF 2021 du• * th• cof￿a￿r￿S pandem* Tr fwsl day the hi4￿YO1Vxr NETS af¥1 knar*es m NET LIagno51￿ Approach. Abstracis have b￿n 8$ and be 10 fv hty¥￿ Ifry¥lP pr•sènt3l#￿s éurino lh• conlerants. Other pL8ns y•*¥Kh￿.. No￿1￿9 8 Iwlher NET5 r(w Newcomers tr¥M4 F•tnary 2021 Ouè w 115 postpwemeni In 2020-h¢kl In May W21. Fuiiher deveWing It* &Prtary d knie Sp1•£￿ thid itwawy ¢bJer gu￿ChneS Oevek)r4ng a Caruntyd Heart D15è8se Conlerw*e Ircffj 2020 DelNery of Wder traning lot n￿￿es. AHPS. GP5. and n￿￿¥pa￿lISt$ OÈ¥ek)pmenl ol 8 INer Iranspl•n¢akn ddwery wogwme and asswaled serfe dèvel0￿anI ¥nd opwtunrtw. fft c(4L•bvatsM ¥rth LAG. NHF8T ¥nd SIGTO Deveknpmenl ol addl￿nI1 t)￿￿8 ¢￿tent IN UKI NETS members UKI NETS cc4yéfflalkryn of Éurr¢ean NÉT slLrt￿ UK NÉT dieletts suryey and gL*J•nce Ann￿1 c4nlererKfr ¢4aThs 10 ¢* wd•rK¢ Cov1￿19 Prowx11ty leédw on oxtem¥ ch￿￿1 guwjdtw Conlinuing lo se¢ure fundrf￿ Ifoffl t￿1• Coftbnuuig to devéh¥ c4y*nWnKa￿T￿4 with fflernl>ws wtykthg ￿1h olhor￿￿elK11 to aryl NETS aTrJ rést¥rch The Trustees Rep￿ wa* •kyovad ty th? 8owd ol TIu5te8s •fvJ sw•d ￿ its b8haN by". ProfT H Shah Trnsle 081ed'. IL UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED INDEPENDENT EXAMINERS REPORT TO THE TRUSTEES OF UK AND IRELAND NEUROENtK)CRINE TUMOUR SOCIErY Um￿E0 I report to Ihe trusthes M my eX8min8l*￿ c4 Ihe $t8tsftwnts ￿ UK and lrnl¥KI Neurc4nth¥ine T￿M￿r S￿ty Limited lor Ihe year 314￿￿$t 2021. Rasponslbllitles •nd basls ol rnport As the tsust8as olthe chanty land also ts direttorn offthmpony l•*) you are respMsible the yeparniv)n of the fwncaal stalernonts •) with Ihe requirements olth¢ Compan*s Ad 2C￿ lthe 2Cth Acll. H8￿r￿￿ salsfied myself Ihat firsanc*l slaternorts o1th8 dwity afo r¢qulred 10 be wjdited undw Part 16 ofthe 2C(kS Act and ar• aTh mdtrt*rnkn)l examina1￿)n. I rewrt ￿ re5P8d of the ex8minakn oltho ch8ntys f￿nts81 sts16mBnts tan*1 out under sact#M 144 ollhe Chafi￿0$ Aci 20111th0 2011 Actl. In unyr¥J rrtrt my examin4lbJTh I havo all the appluNo Diract￿$ gN•n by the Charity coftwTw#￿ ur¥Jer￿a￿￿ 1445Kbloftho 2011A¢ Indop•nd•nt Examln•rf# St•t•r*nt I ha￿ ￿npl•to￿ mu exa￿￿n#￿0Tr. l ￿nfvrn thal rK* mattors havo cm to my attontkn in cannxii wrth the ¢XarnIna￿n gmry mg eause to baliM Ihat in any matthal rgsp8ci.' 1. aectrJnb"ng Terryd5 wwe not k•pt in r85F4d olthe chafty88 re4￿￿j 386 oftho 2( Aei.. ¢Y 3. fv fift￿￿81 8tsthm•nts do corr￿￿￿h t￿ arthxnlrg of 8gCtion 396 01 the 2006 Ath other than any requir•ment thai the 91￿ a tru• 8Tr1 fa*vi8w whSch nol ttér considèrod as p8rt018n indwndenl examin8tson; or 4. tho finar¥aal slatoments ha¥¢ Trjt boon w4parnd kn aCCud8￿ with the mèthcth and Pfind￿•s ol the Stsl8mènl of R8comm¢nded Pra¢tiC8 for ac1X￿n￿￿a and reporting by charitss applK8bh 10 chariDe$ pr•parin9 theira¢c4)unts in wlh thg FinancDI ReportiNJ Slandard ap￿￿ab In the UK and R&wbI￿ of Ir•l8ry1 IFRS 1021.: I have no concerns 8nd have comè across rn 0th8rm8ll?rs with th8 examln81ion to which Bttention should b8 drawn in Ihis f8F(Il in c(dw lo enable a proper under5t8nding olthe finar¥ial slalemnts to b8 rextsd. P8uI Bow8terACA BVSC Acwuntsncy SM First Floor LNery Place 35 LNery Streel 8irrningham 832P8 Oatsd.. 11 0$ UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY UMITED STATEMENT OF FINANCIAL ACTMnES ONCLUDING INCOME AND EXPENDITURE ACCOUNT) YEAR ENDED 31 AUGUST 2021 Unr08tr1cl•d R￿1￿cl•d lund• fvnds Total Total 2021 2021 2021 2020 Donations h8ritabl8 Sponsorship 17,121 17.121 16.544 78.045 78,045 117.983 To¢•1 In¢¢Jn ndltur• on. haritsble adwi R8s88r¢h grant 74.WJ5 10.8( 8S.705 97.691 Tot•1 C￿lIt￿bI• •xp•ndltur• 97,e91 Othw I•$￿5 expe￿ed Total r••oU￿￿ •xp•nd•d Net Incom• for the y•arlN•t mov•m•nt In funds 20,186 {10.8fy)) 36,768 Fund balanc•B al 1 September 2020 103.869 34.325 138,194 101,426 Fund balan¢e• a¢ 31 Aug￿1 2021 124.035 138.194 statement of finanual athitss 8Lw (%)mF4￿$ *ith the requlr&m8nts an IrKcth8 Bnd 8xpendrturn act￿nt mdertho Companth Acl M. UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITEO BALANCE SHEEr AS AT 31 AUGUST 2021 Ilo 2021 2010 Flx•d us•ls Cun•nt as5•11 OebtN5 C•sh èi bank haTrJ 61.327 13.599 136.439 150.038 16J.092 CrndSlL¥J.' tslWn• du• *lth ¢MXy 115.5321 N¢i¢yrr•Dt au•ls 1J8.194 Totsl •M•¢J l••B curr•nl 147.560 138.194 R*$w￿ ruTh un￿5￿￿1ed W$ 14 2).525 124.035 34.325 103.169 147. 138.194 47101 Lho Ctynparl￿kI 2W6 rewrylo sma•ctsYwi•$ 140 meths hw• ww•d the to¢btain an *uOrf ¢11￿ f￿￿81 stswnents Iwtho 31 Au9Ug12021 ￿ accwdance se¢1¥￿4?6 ollh•c¢JTwr￿*5 The tsyslets •ckw*4•&* thwre¥ty¥sibM*s Sy•n5ww4thal thecJWke•ps reetyds Kh compty x•¢w 38641 lty WIp￿j staithThnis*•M¢h grye a Irue and ol Ihfr 5Wle ol•ff•irn olthe ctsiwy•$ al Iho eThJc4 Ihe yo¥1 ind ol As ￿corn Jrcas ¥TrY oliesowces. expoThJ*n. lorlhe fwwnrAal In atc(the wlh th• rnquklQM￿sDIs￿h2ns 394 athj 395 ttyDptywith U pany. The T￿OrK￿91 s￿1￿nLI￿¢re •pm•J by Prt4fHsh 11 UK AND IREIAND NEUROENDOCRINE TUMOUR SOCIETY UMITED li UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED NOTES TO THE FINANCIAL STATEMEP YEAR ENDED 31 AUGUST 2021 1. Aeeoundng Polld A¢¢ountlng ¢onvonUon The accounts ha¥8 ￿eTh wepared in wxdanc¢ tmth Ihe Compani*5 kt 2C¢6 and"ACr￿N￿￿9 and Rewrtmg by Chartl*s.' sts18￿Trt ofRecirfThr*Jed Prath• ISORPI ap￿4￿ble In lh8 UK RewtAi¢ oflreland IFRS 1021.185 ametsjed acoJmtiThJ perK#Js oJmm￿k7n9 from 1 January 20161. T￿? dwity li a"Put* ewefrt Entity a$ ￿fir￿A ty FRS 102. The tharity W lèknn advantsye of th? FThiSthS in thè SORPtstharths apth'ryd FRS 102 Updèto B￿l8￿"n I notto P￿pare a state￿￿t ofC4sh F￿￿. The financ6al ststements have ￿8p¥o0 uThlor I￿ eOSlgyW￿t￿X. Th• wrK4pal accounling pJlits•s adoFlod are ￿ (xrt Golng conc•m Al the lirm 018pwo¥lng the fmartial sts1￿￿ots, the IN5tees hovo a exptttstson Ihat th8 charity has adeqtJ*e r8styJrcrf to o)ntknu8 ID epwat￿l •xlstenc8 fcf th• 1tr6seeable fvlur¥. Thus tsu51885 t¢nbnue to adopt t*[￿arn basB In preparing lh• finan(*l stalermnts. Ch•rttabl• fun un￿trIct￿ hjrrtjs arg avalat40fr* w alts*th￿OIkn M¢l¢o8 In fvrthtr8ne• olthelr Reslrfcted bjnds are SI￿je¢l lo spacth t£￿dit￿%￿ by d￿$ 8$ lo Ihty may be usod. The p￿0$•9 resty**d lthJs are sel wt TrJig5 10 thg fmaThSal $￿I￿nts. Incomlng I•￿U Thew arè induded ￿ thè slat8ft￿lof FiwrKi&l ISOFAl*hon: ha¥8 betrn mel.. Tho trust8es wrtually c4rt8in that Ihey will reCe￿e rescrtxces.. aThJ The monelwy ¥a￿e can b8 MO￿ured Trlthlty. C8sh donat￿ 8Tr reco3ntsed ￿ r8rAW olher (¥K* the ch8rity ha5 been notffi8d of Ihe dmabon. ¢￿drt￿s requ￿ deferr4 olthe amounl. Chanlable inL*the iMaJdes SF￿￿ship (4 ￿ aMu81 Cryffer￿ea and cry￿ribut￿s tmrds the chafi'ty's obiecti¥e& 12 UK AND IRELAND NEVROENDOCRINE TUMOUR SOCIETY UMITED NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2021 1. A¢MunUn9 Pollcl•• Iconllnu•d) R••ourus •xp•nd•d admIn￿trat￿. whth SUPFo1 thg charrtaue purr*)s8. Gran￿ otsed subject to C4N1￿ul8. whk* ha¥e not beon mel at the ￿ar4r￿j date ar• a6 a eommitrnenl. bul not awuod a$ oxpendrtu￿. 89gre981e All ￿SIS rdatod to the tatewy. Whw• wsts tannot be 8iintwi8d to partthlar adings Ihat ha¥• boenak*aled lo a(IMlws (m a ba*% cmtent ￿ th• ol the In¢omlng r••oureM tth r•lthd •x￿ndI￿rn Whon Inwwig reswrt•s r•laW 8xfftttw8 (aal￿th (Urth￿￿j wc*)nlrad trM)th are reported gross #i the SOFA TaTrglbl• Ilx•d ••Mt* Tangible assets aro inilialty measuf•J al (￿land ￿#sUred at ctht or valualh?n. net of depr8&0￿Tr and aThy w*paim￿l b)$8es. D¢preck8kn rs reewtsed so as to it off o)st ¢y valth ofauéts I￿ Ih•w res￿lu41 valu0$ their wlul IN*S on the baws.. Cernputw¥- Ilrnljhl lirw rNW 3 The gawi ￿ k)ss arising rKb Ihe ¢Jisp05al ofan 8sset ts d8teImw￿d 08 the dNlorence th• Sa￿ pr￿eedS and the ￿lu9 olthe 8sset. and i8 feco3ni5od in net irKom81lexpendrturel rt¢ th& year. C••h and ¢￿h •gU￿41•nI$ C8sh and cash equNal•nts irK4LAIo cash n hond. ¢JeF4)Bts hehj 81 call *ith ba￿ other sh￿1 m Iiqu*J investm8nlS ￿th ¢Y#Jinal malurrlies olthree rMThlhs orloss. bank overdraf Bonk ov8rthlLs ara shw ￿rth￿ cwrenl tsablI￿.8$. FInanc￿l In•twument• Tha charity has ekntsd to appty ts prows¥￿ of seth￿ 11 'BaS￿ Firyandal Instruments. S•ction 12.0￿r Issues" ol FRS 102 to *1 ol ils fThrKial w*lruments. F￿8￿￿91 in5t[U￿￿ts are rec(•Jnised in the char￿5 baknr** shtel whon Ihe charity becomes party to tho (%)ntractual prow$i￿ of the ￿￿trUmenL 13 UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIEfY LIMITED NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2020 1. Aceountlng Polkl•• l¢on¢Inu￿) slatements. when there is a *981ty ¥Thf￿Ce8ly1e ryhl lo sei off the recogrllsed aM￿n[S and ihare an intention 10 5e1158 M a basty w lo the assets * sellje Ihg hablty simuttaneousty. B•slc fin•n¢l•l•ss•ts Basic finamal assets. i￿ude debicrf5 and and bank balar*es. are measwed Al tranSact￿n prK8, Ind￿lIng transèciK)n costs are subsequenty rAm8d at am(**sed uslng the effectNe thter8St Thlhc•J unless thè *rnwmOAt ¢Xsn5ts1utss a fmancing trarts8Etion. thè transa¢Uon 1$ ffwured al tho pre58nl value ol Iha frJbJre recepts dL5c•unied ai markel valLta of interest. Finanoal assots dassrfigd as r¥coNa￿fj within year arn Tr)1 amorti$8d. B•sk thMn¢hlll•blllll•¥ Bask fmandal Ikqbiliixs. in&Jdlng ¢>edrf￿ and bank loam are initialty teet¥ntstid at transacts.on price unless lh¢ arrangemenl ctY&sbttrtes o financirrtJ transacts)n. whe¢• the debt instrumenl 1$ measured at the present value of thè fvlur8 payThents thsts)unt8d at a m8rk¢t rate of lThtef•st. Financ4al ligbilil*s as pay8bl¢ *ithin om yoaiar• th)t am￿￿8¢d. D*r¢¢ognltlon oflln•nclal Il•blllU•s Flnanclal Ihbilitw¥ ar• dèrecognSsed ￿ the dwvs conlractrjal •xpire dIsCharg￿ or car￿￿￿. 2. Crltl¢al accounllng ￿tIM*￿• and Judo•m•nts In the 8ppllcptlon of Ihe tlwws acNuniwKJ pJk*s. tho InJst88s wo rnquired to mak• iudg8rnents, 8sllmatè$ and assumptions a￿ul lh8 caw afflount of asset$ and Ilabllitieg that Arè [￿1 r*adlty app8rgnl frorn other sourcts. Th• eslimates and assodated assurnpbons are based on hi$ioric81 exp￿*r￿ and othw factors that arg conshd¢red lo be rel8v8nL Actual r88uIt5 may diller from th•so osts"matg5. The esUm8l•s ond un(Iwtyir& assumptiws arn ro¥itrwed on an orrfJiNJ basts. Ro¥6sions to acrnunting eslimales are recognised in tha period In whith the estimate is revised where ¢he reviS￿n affects only thal pernd. ￿ in tha perKrf1 of Ihe reviS￿n and futyre penods where the revisith) affects bolh cJJrnnt and fulurn periods. 3. Don¥tlons and 1•9acS0• Unre8trS¢t•d Fund• R•stslcled funds Total Total 2021 2021 2021 2020 Donations and gifts Membership fees 2,188 14,359 17.121 17.121 Total for the year 17.121 16.544 14 UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITEO NOTES TO THE FINANCIAL STATEMEKTS YEAR ENDED 31 AUGUST 2021 4. Charllabla •ctlvlt Spon•ty•h* Gr*nt• Total 2021 2021 2021 2020 Sales *4thin chantabl• xts¥ii P•rfomanc• rnLalod granls 78.04S 78.045 117.983 Total ler Ihfr y•ar 78.045 117.983 Analy•l• by fund Unrestricted frjnds Reslrkied fvr 117,983 117983 S. Charttabl• advltl•• 2021 2020 Dfrpredatir￿ and impaimwnt Confer•nc•5 and no*8l&ttern 20.484 42.720 20.484 42.720 Share of SUPF<*I cosls1rn10 61 Share 019ovemance costs Inote 61 Itthn dè¥ekIpfr*￿* costs 29.818 24.603 10,8 27.602 20,169 7,2C 85,705 97,691 Analy•l• by lund Unrestrfcted ILw¥Js R8slricl8d funds 74.￿5 10,800 87.638 10.053 85,705 97,691 Is UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIEfY UMITED NOTES TO THE FINANCIAL STATEMEpirs YEAR ENDED 31 AVGVST 2021 6. Support ¢osts Support Gov•mwK• Tot*1 Total 2021 2021 2020 ENET mernborship S￿￿￿6p￿0nS W8bsrte Managemanl lees Independenl èxamlner accountancy fees Oth•r operatsrg costs Comrnittèa mé•b"ngs 12.178 12.178 7,723 3,679 16,2 14,550 14.550 1.440 18,260 469 18,620 4,543 18.620 4,543 29.818 24.603 Bed Charitable actfvltles 7. Trust••$ Non8 ofthè Irust•es lor any persons Lwnn•¢iod *lth thgml r•c•1￿1 •ny romun¢r¥b)n or bengffts from the thanty duriry the yw12020- tnill. 8. Ernploy••• Th8r& wtr• ￿ •mpby8os durfng th8 y•8r.12020- nll. •. Tanglbl• fix•d a¥s•ts Comput•rs Cost At 1 Seplembar 2020 and 31 August 2021 D•pr¢¢Satlon •nd Irnpal￿tht At 1 Septembar 2020 and 31 August 2021 Carryln9 amount At 31 August 2021 AI 31 August 2020 Charit8ble aclivth'es 16 UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIEfY LIMITED NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2021 10. Flnanclal InstwuTranls 2020 CanyEng amount of flnanelal •ss•ts Debt ￿￿sure￿ at cost C•rryln9 ¥alu• olfftnan¢lal Ilabllltl•• M8a$ured on amorbs¢d o)sts 11. D•btors 2021 2020 Amoun1• falllng du• wlthln on• y￿r 10,¢Xrf) 54.327 10.oc 3.599 12. Cr•dltorJ: •mounts lalllng du• ¥thln on• y•ar Dof8rr•d Incthlè 4.732 lo,￿) 2.312 9,$32 1S,532 13. Oth•r d•l•rf•d Incom• 2021 2020 Other defeThed irwne 17 UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMrrED NOTES TO THE FINANCIAL sTATEMEP￿s YEAR ENDED 31 AUGUST 2021 14. Retylwlcted lund8 In lunds Balanco at 1 Sept¢mb•r 2020 In¢ornlng RMouru• •xp•nd•d Balgne• at31 August 2021 Grants TransNET Mobilo app dèveljpy 11,150 4,925 18,250 11.150 4,925 7.450 10.8(KS 10.8C¥) 15. Anal￿1* of n•1 a•Ws ￿t￿••n fund* Fund balanc•s at 31 Wt 2021 •r¥J 31 202D arè ropr￿on1td by 0Jrr￿t asseWlllablkn¥. 16. Rolai•d party tr•nvdlon Thfrre wwe Tr) d￿d(￿at4• r•lat•d party transKth y•ar12020- r￿1. 18 **UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED** ## **INDEPENDENT EXAMINERS REPORT** ## **TO THE TRUSTEES OF UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED** I report to the trustees on my examination of the financial statements of UK and Ireland Neuroendocrine Tumour Society Limited for the year ending 31 August 2021. ## **Responsibilities and basis of report** As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act). Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for an independent examination. I report in respect of the examination of the charity’s financial statements carried out under section 144 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011Act. ## **Independent Examiner’s Statement** I have completed mu examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect: 1. accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or 2. the financial statements do not accord with those records; or 3. the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or 4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).; I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached. Paul Bowater ACA BVSC Accountancy Services First Floor Livery Place 35 Livery Street Birmingham B3 2PB Dated: 11 July 2022 8